Non Hodgkin Lymphoma Clinical Trial
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin’s Lymphoma
Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which rituximab regimen is more effective in treating indolent non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and comparing them to see how well they work in treating patients with low tumor burden indolent stage III non-Hodgkin's lymphoma or stage IV non-Hodgkin's lymphoma.
Full Description
OBJECTIVES:
Primary
To compare time to rituximab failure between the rituximab scheduled and rituximab retreatment arms.
Secondary
To compare the time to first cytotoxic therapy between the rituximab scheduled and rituximab retreatment arms.
To document the rationale for beginning cytotoxic therapy; defined as chemotherapy, radiation therapy or radioimmunotherapy.
To compare the toxicities associated with rituximab therapy between the two randomized treatment arms.
Quality of Life Objectives:
To compare health-related quality of life, distress, psychological functioning, physical well-being and functional well-being of patients receiving rituximab scheduled to those receiving rituximab retreatment.
To examine the impact of differential treatment response (delayed time to rituximab failure and/or time to first cytotoxic therapy), if observed, on quality of life, distress, and psychological functioning on patients receiving rituximab scheduled to those receiving rituximab retreatment.
To obtain prospective data on physical and functional well-being during treatment with rituximab.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to histologic subtype (follicular vs other), age (under 60 vs 60 and over), and the time from diagnosis (less than 1 year vs at least 1 year).
Induction rituximab: Patients receive rituximab Intravenous (IV) once a week for 4 weeks.
Patients are re-evaluated 9 weeks after the completion of induction rituximab. Patients with a partial or complete response to induction rituximab are randomized to 1 of 2 treatment arms.
Arm A (retreatment rituximab): Patients receive rituximab IV once a week for 4 weeks upon disease progression provided time to progression is more than 6 months.
Arm B (scheduled rituximab): Patients receive a single dose of rituximab IV once every 13 weeks until disease progression and in the absence of unacceptable toxicity.
Quality of life is assessed after induction rituximab treatment and at 26, 39, 65, 117, 169, and 221 weeks after randomization.
Patients are followed at least annually for 15 years from study entry.
Eligibility Criteria
INCLUSION CRITERIA:
Histologically confirmed non-Hodgkin's lymphoma, including 1 of the following:
Follicular grade 1 or 2
Small lymphocytic
Marginal zone (nodal)
Marginal zone (splenic)
Mucosa-associated lymphoid tissue (MALT)
Stage III or IV disease
Must meet the following criteria for low tumor burden:
No nodal or extranodal mass at least 7 cm
Less than 3 nodal masses greater than 3 cm in diameter
No systemic symptoms or B symptoms
No splenomegaly greater than 16 cm by a computed tomography (CT) scan
No evidence of risk of compression of a vital organ (i.e., ureteral or epidural)
No leukemic phase with greater than 5,000/mm^3 circulating lymphocytes
No cytopenias, defined as any of the following:
Platelet count less than 100,000/mm^3
Hemoglobin less than 10 g/dL
Absolute neutrophil count less than 1,500/mm^3
At least 1 objective measurable disease parameter
Abnormal positron emission tomography (PET) scans will not constitute evaluable disease unless verified by CT scan or other appropriate imaging
Age: 18 and over
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Must meet the following criteria for labs:
Hematopoietic
Absolute neutrophil count at least 1,500/mm^3*
Hemoglobin at least 10 g/dL*
Platelet count at least 100,000/mm^3*
NOTE: *Without growth factor and/or transfusion support
Hepatic
Bilirubin no greater than 2 times upper limit of normal (ULN) OR direct bilirubin normal for patients with Gilbert's Syndrome
The aspartate transaminase (AST) and alanine transaminase (ALT) ratio (AST/ALT) no greater than 5 times ULN
Hepatitis B surface antigen negative
Renal
Creatinine no greater than 2 times ULN
EXCLUSION CRITERIA:
Evidence of transformation to a large cell histology
Pregnant or nursing. Fertile patients must use effective contraception
HIV positive
Uncontrolled active infection
Other malignancy within the past 2 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
Prior immunotherapy for lymphoma
Prior chemotherapy for lymphoma
Concurrent chemotherapy
Prior radiotherapy for lymphoma
Concurrent radiotherapy
Concurrent radioimmunotherapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.